#United States #Unisys #Blue Bell, Pennsylvania #Pharmacology #Trustworthy AI

Unisys Pioneers Trustworthy AI Research in Drug Repurposing

Unisys Corporation, a prominent player in technology solutions, has recently made headlines with the release of a peer-reviewed paper titled "From benchmark accuracy to pharmacological credibility: why mechanistic explainability must define the next generation of AI for drug repurposing." This research was published in the respected journal, Frontiers in Pharmacology, and addresses critical challenges in AI deployment, particularly in the healthcare sector and other heavily regulated industries.

Bridging the Trust Gap in AI

AI's rapid advancement has sparked significant interest across various sectors, but its adoption in healthcare remains cautious due to trust issues. Many existing AI systems can produce outputs without providing a clear rationale, leading to skepticism amongst healthcare organizations. This lack of transparency complicates the assessment and reliance on AI-generated recommendations.

To tackle this issue, Unisys advocates for a neurosymbolic AI approach, a method that combines advanced AI techniques with the nuance of human expertise and reasoning. This fusion aims to enhance understanding and clarity in the AI decision-making process, fostering trust and credibility.

Introducing the MURP Framework

A core part of Unisys' research is the introduction of the MURP framework—Mechanistic Coherence, Uncertainty, Robustness, and Provenance. This innovative framework expands the benchmarks of AI evaluation beyond just predictive accuracy, incorporating essential criteria that are particularly relevant for applications in highly regulated fields like pharmaceuticals.

Salvatore Sinno, the Vice President of Innovation at Unisys, emphasized the importance of integrating credibility into the future landscape of AI. "The next phase of AI innovation will be shaped not only by performance, but by credibility," he noted, highlighting how organizations are increasingly scrutinizing AI within complex, regulated environments. It is now crucial to ensure that AI-driven outcomes are not only effective but also governable and trustworthy.

From Research to Real-World Application

Unisys’ dedication to advancing AI doesn't stop at theoretical frameworks. This study is part of a broader movement within the company to translate emerging capabilities into tangible business value. Alongside this publication, Unisys has also released findings from the Unisys AI Cloud Insights Report 2026, further supporting their AI-First strategy aimed at transitioning organizations from mere experimentation to scalable applications in real life.

Conclusion

As the healthcare industry continues to embrace AI, the work conducted at Unisys provides vital insights that could reshape the trust landscape. By focusing on explainability and robustness, they are paving the way for more reliable and responsible AI usage in drug repurposing and beyond. Their research not only marks a substantial step forward in AI application but also underscores a commitment to ethical standards and regulatory compliance.

To explore the full scale of their findings, you can read the published paper in Frontiers in Pharmacology and discover more about Unisys' AI offerings today. For further information on Unisys, visit unisys.com and see how they are pushing the boundaries of technology and innovation, having confidently supported clients for more than 150 years.